<DOC>
	<DOCNO>NCT01048593</DOCNO>
	<brief_summary>This study test efficacy safety IBI-10090 reduction ocular inflammation cataract surgery .</brief_summary>
	<brief_title>Efficacy Safety Study IBI-10090 Patients Undergoing Cataract Surgery</brief_title>
	<detailed_description>All patient receive active treatment study . Dose group 1 receive 114ug dexamethasone , Dose group 2 receive 513ug Dose group 3 receive 684ug .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Male female patient 40 year age schedule unilateral cataract surgery ( phacoemulsification extracapsular extraction ) posterior chamber intraocular lens implantation . Patients use ocular , topical oral corticosteroid within 7 day prior Day 0 . Patients use topical ocular NSAIDs study eye within 15 day prior screen . Patients sign intraocular inflammation either eye screening . Patients receive prior intravitreal injection study eye .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>ocular inflammation cataract surgery</keyword>
	<keyword>post cataract surgery inflammation</keyword>
</DOC>